Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting
November 15, 2021 08:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference
November 09, 2021 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Oncternal Therapeutics
Progressed the development of zilovertamab (formerly cirmtuzumab) for the treatment of patients with mantle cell lymphoma, including ongoing interactions with the US FDA on potential registration...
Oncternal Therapeutics Joins Karolinska Institutet’s NextGenNK Competence Center for the Development of Next Generation NK Cell-Based Cancer Immunotherapies
November 03, 2021 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board
November 02, 2021 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2021 16:05 ET
|
Oncternal Therapeutics
SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results
October 29, 2021 08:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 05, 2021 16:05 ET
|
Oncternal Therapeutics
Androgen Receptor (AR) inhibition is an important therapeutic approach for the treatment of Castration-Resistant Prostate Cancer (CRPC), but AR-escape mechanisms related to the expression of AR splice...
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 01, 2021 16:01 ET
|
Oncternal Therapeutics
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
September 20, 2021 08:00 ET
|
Oncternal Therapeutics; Celularity Inc.
SAN DIEGO and FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (“Oncternal”) (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development...